BRAF and thyroid cancer, nonmedullary, 2: All thyroid neoplasm samples were tested for the presence of BRAF V600E mutation, which was reported to be prevalent in papillary and anaplastic thyroid carcinomas, unlike in FTC and benign thyroid nodules [26–28].